Case Comprehensive Cancer Center, University Hospitals Seidman Cancer Center

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)	B-cell chronic lymphocytic leukemia, B-cell neoplasm, Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Leukemia, B-Cell, Lymphoma, B-Cell, Marginal Zone, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, diffuse large B-cell lymphoma, follicular lymphoma, hematologic disorder, high grade B-cell lymphoma, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoma, lymphoproliferative syndrome, mantle cell lymphoma, marginal zone lymphoma, neoplasm, non-Hodgkin lymphoma	Recruiting	Phase 1	2026-09-09		NCT07225439

Clinical trials